Zenith开窗支架治疗近肾腹主动脉瘤的美国前瞻性多中心研究5年最终结果
该研究前瞻性纳入美国14个中心67例近肾腹主动脉瘤患者,评估Zenith开窗支架5年结局。中位随访59.8个月,全因死亡率免于发生率为88.8±4.2%,动脉瘤相关死亡率免于发生率为96.8±2.3%,无动脉瘤破裂或开放转换,肾支架闭塞率4%、支架内狭窄率11%,81%患者瘤囊缩小。
要点
- 5年全因死亡率免于发生率为88.8±4.2%,动脉瘤相关死亡率免于发生率为96.8±2.3%
- 肾动脉支架原发和继发通畅率分别为82.7±4.1%和95.7±2.1%
- 裸金属肾支架内狭窄是二次干预最常见指征,占20例中的12例
核心结论
- 5年结果证实Zenith开窗支架治疗近肾腹主动脉瘤安全有效,无晚期移植物或动脉瘤相关死亡。
- 裸金属肾支架内狭窄是二次干预最常见指征。
- IA型内漏、瘤囊增大和装置迁移发生率低,支持其用于近肾腹主动脉瘤患者。
研究设计与样本
- 前瞻性、多中心研究,2005至2012年在美国14个中心纳入67例近肾腹主动脉瘤患者(54例男性,平均年龄74±8岁)。
- 使用开窗支架治疗肾下主动脉颈长度4至14 mm的患者, targeting 178条肾-肠系膜动脉,平均每例2.7条血管。
- 5年时67例中42例完成最终随访,41例接受临床检查,39例接受CT影像。
- 结局由临床事件委员会裁定,包括全因和动脉瘤相关死亡、主要不良事件、肾支架闭塞/狭窄、肾功能变化和肾梗死、瘤囊增大(>5 mm)、装置迁移(≥10 mm)、I/III型内漏和二次干预。
主要发现
- 中位随访59.8个月(范围0.1-67.5个月),共7例死亡,其中1例(1.5%)为30天内手术相关死亡,6例为30天后死亡(5例非手术相关,1例不确定)。
- 5年全因死亡率免于发生率为88.8±4.2%,动脉瘤相关死亡率免于发生率为96.8±2.3%,无动脉瘤破裂或开放转换。
- 129条开窗靶向肾动脉中,5条(4%)闭塞,14条(11%)发生支架内狭窄;治疗包括13条血管再次支架/血管成形、2条肾动脉旁路、1条血栓切除失败。
- 5年肾动脉靶血管原发和继发通畅率分别为82.7±4.1%和95.7±2.1%;1例既往慢性肾病患者需要透析。
- 5年内发生1例IA型内漏(1.5%)、1例IB型内漏(1.5%)、2例装置迁移(3%)、4例瘤囊增大(6%);81%患者5年时瘤囊缩小。
临床怎么用
- 对于近肾腹主动脉瘤且肾下主动脉颈长度4至14 mm的患者,Zenith开窗支架可作为安全有效的治疗选择。
- 术后需重点监测肾动脉支架通畅性,因支架内狭窄是二次干预最常见原因。
- 5年随访中IA型内漏、瘤囊增大和装置迁移发生率低,支持该装置的持久性。
局限性
- 5年时仅42/67例完成最终随访,存在随访丢失。
- 单臂研究,无对照组。
- 样本量较小(67例),来自14个中心。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To report 5-year results of the prospective, multicenter study designed to evaluate the Zenith Fenestrated AAA Endovascular Graft (William A. Cook Australia, Brisbane, Australia) for juxtarenal abdominal aortic aneurysms (AAAs). METHODS: Sixty-seven patients (54 male, mean age 74 ± 8 years) were prospectively enrolled at 14 U.S. centers from 2005 to 2012. Fenestrated stent grafts were used in patients with infrarenal aortic neck lengths of 4 to 14 mm to target 178 renal-mesenteric arteries with a mean of 2.7 vessels per patient. At 5 years, 42 of the 67 patients completed the final study follow-up, with clinical examination obtained in 41 and computed tomography imaging in 39. Outcomes adjudicated by a clinical events committee included all-cause and aneurysm-related mortality, major adverse events, renal stent occlusion/stenosis, renal function changes and renal infarcts, aneurysm sac enlargement (>5 mm), device migration (≥10 mm), type I/III endoleak, and secondary interventions. RESULTS: Median follow-up was 59.8 months (range, 0.1-67.5 months). There were seven deaths, including one (1.5%) within 30 days (procedure-related) and six beyond 30 days (not procedure-related in five, indeterminate in one). At 5 years, freedom from all-cause mortality was 88.8 ± 4.2% and freedom from aneurysm-related mortality was 96.8 ± 2.3%. There were no aneurysm ruptures or conversions to open surgery. Of the 129 renal arteries targeted by fenestrations, five (4%) occluded and 14 (11%) developed in-stent stenosis. Treatment included redo stenting/angioplasty in 13 vessels, renal artery bypass in 2 vessels, and failed thrombectomy in 1 vessel. Primary and secondary renal target patency was 82.7 ± 4.1% and 95.7 ± 2.1% at 5 years, respectively. Dialysis was required in one patient who had pre-existing chronic kidney disease. During the 5 years, there was 1 type IA endoleak (1.5%), 1 type IB endoleak (1.5%), 2 device migrations (3%), and 4 aneurysm sac enlargements (6%). Overall, 81% of patients had sac shrinkage at 5 years. Of 20 patients who underwent secondary interventions, 12 were for renal in-stent stenosis or occlusion, 7 were for endoleak, and 1 was for both indications. Freedom from secondary intervention was 63.5 ± 7.2% at 5 years. CONCLUSIONS: These 5-year results confirm the safety and effectiveness of the Zenith Fenestrated AAA stent graft with no late graft- or aneurysm-related deaths. In-stent stenosis of bare metal renal stents was the most frequent indication for secondary intervention. The low rate of type IA endoleak, sac enlargement, and device migration support its use in patients with juxtarenal AAAs.
引用
- Oderich GS, Farber MA, Schneider D, et al. Final 5-year results of the United States Zenith Fenestrated prospective multicenter study for juxtarenal abdominal aortic aneurysms. J Vasc Surg. 2020. PMID: 32891806. doi:10.1016/j.jvs.2020.08.128
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。